Chimeric receptors to DLL3 and methods of use thereof
US12012462B2 · kind B2 · utility
0Cited by
17References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 10, 2019 |
| Grant date | Jun 18, 2024 |
| Priority date | — |
| Expiry date | Feb 8, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15041
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.